住院肺结核患者体液免疫水平的变化及其临床意义  

Effects of chemotherapy on humoral immune of tuberculosis patients and analysis of it's clinical significance

作　　者：匡铁吉[1] 宋萍[1] 金关甫[1] 王仲元[1] 朱琳[1] 

机构地区：[1]解放军309医院

出　　处：《军医进修学院学报》1996年第3期178-181,共4页Academic Journal of Pla Postgraduate Medical School

摘　　要：本文通过对４８例住院化疗肺结核患者的体液免疫水平进行为期４～５个月的监测，发现：接受标准化疗后的肺结核患者产生３种不同的体液免疫反应模式：６６．６％的肺结核患者接受化疗后，其血清抗结核ＩｇＧ抗体在较高水平上持续升高，经１～３个月达到最高值，然后平缓下降；１８．７％的肺结核患者在化疗后，其血清特异性ＩｇＧ抗体维持较高水平，无升高后平缓下降，或在阳性值上下维持不变；还有１４．６％的患者，血清特异性抗体水平低，接受化疗后不产生体液免疫反应。有５例肺结核患者其血清特异性抗体水平在观察期间呈现周期性波动。Through the surveilance of humoral immune levels in 48 patients hospitalized with pulmonary tuberculosis under chemotherapy for 4-5 months, it was found that there are three different modes of humoral immune response among the patients after treatment. 66.6% of the patients showed a rising level of antimycobacterial antibodies in thire sera which reached the maxinum after 1-3 month treatment and then decreased slowly, 18.7% of the patients whose sera contained higher level of antimycobacterial antibodies at the beginning of treatment showed a slowly drop in the level of the antibodies after treatment; 14.6% of them whose sera contained low level of specific antibodies had no humoral immune response. The specific antibody levels in five patients during the surveilance period showed a periodic change. The results in the present paper showed that under the effect of chemotherapy the increased humoral immune response may play a protective role.

关 键 词：肺结核 体液免疫 药物疗法 

分 类 号：R521.03[医药卫生—内科学]